Although suppression of these inflammatory signals using dexamethasone (35), IL-1 and IL-6 inhibitors (30), anticomplement agents (36, 37), and JAK1/2 inhibitors such as baricitinib (38) had varying levels of success in mitigating the morbidity and mortality of acute COVID-19, there are no data concerning their efficacy in preventing or treating PASC. This evidence concerns the gene IL6 and COVID-19.